Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial
Ji Yao Wang,Jasmohan S. Bajaj,Jiang Bin Wang,Jia Shang,Xin Min Zhou,Xiao Lin Guo,Xuan Zhu,Li Na Meng,Hai Xing Jiang,Yu Qiang Mi,Jian Ming Xu,Jin Hui Yang,Bai Song Wang,Ning Ping Zhang
DOI: https://doi.org/10.1111/1751-2980.12816
2019-10-01
Journal of Digestive Diseases
Abstract:<h3 class="article-section__sub-title section1"> Aim</h3><p>Lactulose is effective in the treatment and prevention of overt hepatic encephalopathy (OHE), but there is limited data of lactulose use on microbiota in relations to MHE recovery. The present study is to assess the efficacy of lactulose in recovery of MHE in aspects of cognitive function, QoL and impact on intestinal microbiota.</p><h3 class="article-section__sub-title section1"> Methods</h3><p>This multicenter, randomized, open label controlled trial was conducted in 11 teaching hospitals in China. Participants were randomly allocated 2:1 to receive lactulose (Gp‐L), or no therapy as control (Gp‐NL) for 60 days. The primary endpoint was the MHE reversal rate. Gut microbiota were compared between MHE patients and healthy volunteers, as well as lactulose‐responders and non‐responders.</p><h3 class="article-section__sub-title section1"> Results</h3><p>A total of 98 cirrhotic patients were included in the study, with 31 patients in the Gp‐NL group and 67 patients in the Gp‐L group. At day 60, the MHE reversal rate in Gp‐L (64.18%) was significantly higher than that in Gp‐NL (22.58%) (<i>p</i>=0.0002) with RR 0.46(95%CI 0.32, 0.67).NNT is 2.4. Further, there was significantly more improvement in physical functioning in Gp‐L (4.62±6.16) than in Gp‐NL (1.50±5.34) (<i>p=</i>0.0212). Proteobacteria was significantly higher in MHE patients compared with healthy volunteers (12.27% vs 4.65%, <i>p</i><0.05). Significant differences were found between lactulose responders and non‐responders in Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria. </p><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Treatment with lactulose significantly improves MHE recovery rate , and gut microbiota change in MHE patients can modulate the effectiveness of this therapy. Chinese Clinical Trial Register (ChiCTR) (ID: ChiCTR‐TRC‐12002342).</p><p>This article is protected by copyright. All rights reserved.</p>
gastroenterology & hepatology